Nektar Therapeutics

  www.nektar.com
  www.nektar.com

Nektar Therapeutics Reviews

25 Reviews
3.2
25 Reviews
Rating Trends

Recommend to a friend
Approve of CEO
Nektar Therapeutics President, CEO, and Director Howard W. Robin
Howard W. Robin
19 Ratings
  1.  

    Rock solid pay, innovative environment, knowledgeable colleagues

    • Comp & Benefits
    • Work/Life Balance
    • Senior Management
    • Culture & Values
    Current Employee - Biochemist ( Senior Process Development Engineer) in Huntsville, AL
    Current Employee - Biochemist ( Senior Process Development Engineer) in Huntsville, AL

    I have been working at Nektar Therapeutics full-time (less than an year)

    Pros

    Rock solid pay, innovative environment, knowledgeable colleagues

    Cons

    Business is uncertain due to market conditions.

    Recommends
    Positive Outlook
    Approves of CEO

Nektar Therapeutics Interviews

Updated Sep 11, 2014
Updated Sep 11, 2014

Interview Experience

Interview Experience

75%
12%
12%

Getting an Interview

Getting an Interview

70%
10%
10%

Interview Difficulty

2.9
Average

Interview Difficulty

Hard

Average

Easy
  1.  

    QA Interview

    Anonymous Interview Candidate in San Francisco, CA
    Anonymous Interview Candidate in San Francisco, CA
    Application Details

    I applied online. The process took 3+ monthsinterviewed at Nektar Therapeutics.

    Interview Details

    Good process, and very thorough; but took way too long to finally get an offer and start date.

    Interview Questions
    Negotiation Details
    Rigid, inflexible
    Accepted Offer
    Positive Experience
    Average Interview

Nektar Therapeutics Awards & Accolades

Something missing? Add an award
Best Places to Work for Commuters, National Center for Transit Research at USF, 2012

Additional Info

Unlock Profile
Website www.nektar.com
Headquarters San Francisco, CA
Size 150 to 499 Employees
Founded 1990
Type Company - Public (NKTR)
Industry Biotech & Pharmaceuticals
Revenue $100 to $500 million (USD) per year

Nektar Therapeutics has pegged its fortunes to making drugs more effective. The clinical-stage drug development firm uses its PEGylation technology, (based upon polyethylene glycol) to improve the delivery and efficacy of existing drugs. Nektar's pipeline is focused on anti-infectives and anti-virals, immunology, oncology, and pain treatments. Its lead candidate NKTR-118 (which it is developing in collaboration with AstraZeneca) is being tested as a treatment for opioid-induced constipation. It also maintains a handful of preclinical candidates. Nektar receives royalties... More

Work at Nektar Therapeutics? Share Your Experiences

Nektar Therapeutics

 
Click to Rate
or